Sector News

Merck scouts replacements for CEO Frazier less than a year after scrapping retirement rule: report

June 20, 2019
Life sciences

It was less than a year ago that Merck’s board scrapped a policy that CEOs must retire at the age of 65 in a move designed to keep Ken Frazier around longer. Now, the company is scouting replacements for the long-tenured helmsman, Bloomberg reports.

Merck is preparing for Frazier’s exit and has kicked off a search for potential replacements with a preference for an internal candidate, the news service says, citing sources familiar with the process. The drugmaker is also preparing for the exit of R&D head Roger Perlmutter, according to the report.

A Merck representative didn’t immediately respond to a request for comment from FiercePharma.

Frazier joined Merck in 1992 and has served as CEO since 2011; he’s also the board’s chairman. Last year, the company’s board did away with a rule requiring CEOs to retire at the age of 65, allowing Frazier to stay on past his birthday in December.

In recent years, Frazier has presided over a period of growth fueled partly by the megablockbuster cancer drug Keytruda, sales of which passed $7 billion for 2018. But recently, some analysts and investors have questioned how Merck plans to grow beyond the successful med. Merck’s sales last year grew 5% to $42.3 billion.

One Bloomberg source listed the drugmaker’s chief commercial officer Frank Clyburn, its chief financial officer Robert Davis and its chief marketing officer Michael Nally as potential CEO replacements.

Wednesday’s report comes after the company parted ways with global human health head Adam Schechter, who led a three-decade career at the drugmaker. He’s set to become CEO of LabCorp.

The development also comes amid a series of executive moves in biopharma. Roche’s former pharma head Daniel O’Day recently jumped to lead Gilead Sciences, and Sanofi this month said its CEO Olivier Brandicourt is retiring. Replacing Brandicourt will be former Novartis executive Paul Hudson.

Meanwhile, Merck is hosting an investor day Thursday—its first in five years—and will talk up plans to bolster M&A activity, The Wall Street Journal reported Wednesday. The company has inked some bolt-on deals in Peloton and Tilos.

By Eric Sagonowsky

Source: Fierce Pharma

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach